Protalix BioTherapeutics (PLX) Non-Current Debt (2011 - 2017)

Protalix BioTherapeutics' Non-Current Debt history runs 6 years deep, the most recent figure standing at $4.3 million for Q3 2017.

• On a quarterly basis, Non-Current Debt changed 0.0% year-over-year to $4.3 million in Q3 2017; TTM through Sep 2017 was $4.3 million, a 0.0% change from a year earlier, with the FY2016 full-year figure at $4.3 million, changed 0.0% from the prior year.
• Non-Current Debt steadied at $4.3 million in Q3 2017 per PLX's latest filing, from $4.3 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $4.3 million in Q4 2015 and bottomed at $376000.0 in Q2 2013.
• The 4-year median for Non-Current Debt is $4.3 million (2015), against an average of $3.6 million.
• Across the five-year window, Non-Current Debt slumped 91.97% in 2013 and changed 0.0% in 2016, its largest moves.
• Year by year, Non-Current Debt stood at $2.4 million in 2013, then soared by 81.4% to $4.3 million in 2015, then changed by 0.0% to $4.3 million in 2016, then changed by 0.0% to $4.3 million in 2017.
• Per Business Quant, the three latest PLX Non-Current Debt figures stand at $4.3 million (Q3 2017), $4.3 million (Q2 2017), and $4.3 million (Q1 2017).